Myelodysplastic Syndromes — Lower-Risk (IPSS-R very low / low / intermediate) · Lenalidomide for del(5q) LR-MDS

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-LENALIDOMIDE-MDS-DEL5Q`

ID	`IND-MDS-LR-LENALIDOMIDE-DEL5Q`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-MDS-LR`
Sources	`SRC-ESMO-MDS-2021` `SRC-MDS-004-FENAUX-2011` `SRC-NCCN-AML-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 1L for del(5q) LR-MDS transfusion-dependent. Lenalidomide reimbursed in Ukraine. TP53 testing critical — alters prognosis + alloHCT consideration.

Used By

Algorithms

ALGO-MDS-LR-1L - ALGO-MDS-LR-1L
ALGO-MDS-LR-2L - ALGO-MDS-LR-2L